PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA

被引：0
|
作者：
Amin, A. [1 ]
Taylor, R. [2 ]
Alonso, A. [3 ]
Schwenke, C. [4 ]
Gaudig, M. [5 ]
Gaugris, S. [6 ]
Welten, H. [7 ]
Erhardt, W. [8 ]
Roberts, G. [1 ]
O'Leary, M. [1 ]
Wasserman, M. [9 ]
机构：
[1] Double Helix Consulting, London, England
[2] Univ Exeter, Sch Med, Exeter, Devon, England
[3] Maastricht Univ, Maastricht, Netherlands
[4] SCO SSiS, Berlin, Germany
[5] Janssen, EMEA Hlth Econ & Market Access, Neuss, Germany
[6] Janssen, Outcomes Res, High Wycombe, Bucks, England
[7] Janssen Cilag BV, Hlth Econ & Market Access, Tilburg, Netherlands
[8] Janssen Cilag GmbH, Hlth Econ & Market Access, Neuss, Germany
[9] Double Helix Consulting, Singapore, Singapore
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1526
引用
收藏
页码：591 / 591
页数：1
相关论文
共 50 条
  • [41] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
  • [42] Progression-Free Survival: Does a Correlation With Survival Justify Its Role as a Surrogate Clinical Endpoint?
    Becker, Andreas
    Eichelberg, Christian
    Sun, Maxine
    [J]. CANCER, 2014, 120 (01) : 7 - 10
  • [43] Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis
    Beauchemin, C.
    Johnston, J. B.
    Lapierre, M. E.
    Aissa, F.
    Lachaine, J.
    [J]. CURRENT ONCOLOGY, 2015, 22 (03) : E148 - E156
  • [44] Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
    Pawlyn, Charlotte
    Schjesvold, Fredrik H.
    Cairns, David A.
    Wei, L. J.
    Davies, Faith
    Nadeem, Omar
    Abdulhaq, Haifaa
    Mateos, Maria-Victoria
    Laubach, Jacob
    Weisel, Katja
    Ludwig, Heinz
    Rajkumar, S. Vincent
    Sonneveld, Pieter
    Jackson, Graham
    Morgan, Gareth
    Richardson, Paul G.
    [J]. BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [45] Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
    Han, Kelong
    Ren, Melanie
    Wick, Wolfgang
    Abrey, Lauren
    Das, Asha
    Jin, Jin
    Reardon, David A.
    [J]. NEURO-ONCOLOGY, 2014, 16 (05) : 696 - 706
  • [46] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 345 - +
  • [47] Reply to progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?
    Halabi, Susan
    Rini, Brian I.
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    [J]. CANCER, 2015, 121 (11) : 1906 - 1907
  • [48] Progression-free survival as endpoint in metastatic RCC?
    Knox, Jennifer J.
    [J]. LANCET, 2008, 372 (9637): : 427 - 429
  • [49] Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
    Mushti, Sirisha L.
    Mulkey, Flora
    Sridhara, Rajeshwari
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (10) : 2268 - 2275
  • [50] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
12345